BiTE Amgen For Long-Term Returns
Amgen is among the oldest of the biotechnology companies, with an IPO back in 1983. After building up a portfolio of very profitable drugs, it has seen revenue flatten lately as generic competitors have entered the market for some of those drugs .
from Biotech News
0 Comments